BR112015005161A2 - etanercepte corretamente dobrado em alta pureza e excelente rendimento - Google Patents

etanercepte corretamente dobrado em alta pureza e excelente rendimento

Info

Publication number
BR112015005161A2
BR112015005161A2 BR112015005161A BR112015005161A BR112015005161A2 BR 112015005161 A2 BR112015005161 A2 BR 112015005161A2 BR 112015005161 A BR112015005161 A BR 112015005161A BR 112015005161 A BR112015005161 A BR 112015005161A BR 112015005161 A2 BR112015005161 A2 BR 112015005161A2
Authority
BR
Brazil
Prior art keywords
etanercept
correctly folded
high purity
folded
preparations
Prior art date
Application number
BR112015005161A
Other languages
English (en)
Portuguese (pt)
Inventor
Farrar Douglas
Arakawa Tsutomu
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50233493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015005161(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of BR112015005161A2 publication Critical patent/BR112015005161A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112015005161A 2012-09-11 2013-09-10 etanercepte corretamente dobrado em alta pureza e excelente rendimento BR112015005161A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261699552P 2012-09-11 2012-09-11
PCT/US2013/058994 WO2014043103A1 (en) 2012-09-11 2013-09-10 Correctly folded etanercept in high purity and excellent yield

Publications (1)

Publication Number Publication Date
BR112015005161A2 true BR112015005161A2 (pt) 2017-07-04

Family

ID=50233493

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015005161A BR112015005161A2 (pt) 2012-09-11 2013-09-10 etanercepte corretamente dobrado em alta pureza e excelente rendimento

Country Status (32)

Country Link
US (6) US20140072560A1 (sl)
EP (1) EP2895188B1 (sl)
JP (3) JP2015533797A (sl)
KR (2) KR102250937B1 (sl)
CN (2) CN110051823A (sl)
AR (1) AR092532A1 (sl)
AU (2) AU2013315750B9 (sl)
BR (1) BR112015005161A2 (sl)
CA (1) CA2882551A1 (sl)
CL (1) CL2015000572A1 (sl)
CO (1) CO7400876A2 (sl)
CY (1) CY1120062T1 (sl)
DK (1) DK2895188T3 (sl)
DO (1) DOP2015000055A (sl)
EA (1) EA031324B1 (sl)
EC (1) ECSP15014138A (sl)
ES (1) ES2657377T3 (sl)
HR (1) HRP20180182T1 (sl)
HU (1) HUE036524T2 (sl)
IL (2) IL237311B (sl)
IN (1) IN2015KN00452A (sl)
LT (1) LT2895188T (sl)
MX (2) MX360044B (sl)
NO (1) NO2972131T3 (sl)
PE (2) PE20200607A1 (sl)
PL (1) PL2895188T3 (sl)
PT (1) PT2895188T (sl)
RS (1) RS57013B1 (sl)
SG (1) SG11201501460RA (sl)
SI (1) SI2895188T1 (sl)
TW (2) TWI609877B (sl)
WO (1) WO2014043103A1 (sl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006259664A1 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
PT2768525T (pt) 2011-10-18 2019-07-17 Coherus Biosciences Inc Formulações etanercept estabilizadas com iões de magnésio
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
ES2657377T3 (es) * 2012-09-11 2018-03-05 Coherus Biosciences, Inc. Etanercept plegado correctamente con alta pureza y excelente rendimiento
CN106536565A (zh) * 2014-06-13 2017-03-22 鲁宾有限公司 一种用于纯化TNFR‑Fc融合蛋白的方法
ES2733298T3 (es) 2014-07-18 2019-11-28 Sandoz Ag Cuantificación de TNFR2:Fc plegado erróneamente
RU2670166C1 (ru) * 2014-12-31 2018-10-18 ЭлДжи КЕМ, ЛТД. Способ получения слитого белка tnfr-fc с заданным содержанием примесей
WO2016149139A1 (en) 2015-03-13 2016-09-22 Samsung Bioepis Co., Ltd. Anti-tnf-alpha polypeptide composition and use thereof
EP3377513A1 (en) * 2015-11-18 2018-09-26 Merck Patent GmbH Improved protein separation in ion exchange chromatography
MX2018005831A (es) * 2015-11-18 2018-08-01 Merck Patent Gmbh Gradientes de ph-sal opuestos para separaciones de proteina mejoradas.
KR20190039929A (ko) * 2016-06-17 2019-04-16 제넨테크, 인크. 다중 특이적 항체의 정제
CN114917185B (zh) 2016-10-21 2023-11-14 美国安进公司 药物配制品及其制备方法
EP3601332A1 (en) * 2017-03-24 2020-02-05 Council of Scientific and Industrial Research A process for the purification of recombinant antibody fragments
US11253569B2 (en) 2018-05-03 2022-02-22 Seattle Children's Hospital Methods of treating Kawasaki Disease
CN112876567A (zh) * 2019-11-29 2021-06-01 广东菲鹏制药股份有限公司 Fc融合蛋白及其纯化方法
US20240156907A1 (en) * 2021-03-16 2024-05-16 Kashiv Biosciences, Llc Novel formulation of fusion protein
WO2022234412A1 (en) * 2021-05-03 2022-11-10 Lupin Limited A process for purification of fc-fusion proteins

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
ATE236249T1 (de) 1989-09-12 2003-04-15 Hoffmann La Roche Tfn-bindende proteine
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
DE59109032D1 (de) 1990-06-28 1998-09-03 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre Herstellung und Verwendung
KR100232688B1 (ko) 1992-09-15 1999-12-01 스코트 쥐. 홀퀴스트 종양 괴사 인자 길항제를 함유하는 tnf-의존성 염증 치료용 제약 조성물
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
AU4363200A (en) 1999-04-19 2000-11-02 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical desorders
CA2399436A1 (en) 2000-02-10 2001-08-16 Loran Marie Killar Method of treating or inhibiting cellular injury or cell death
ES2477996T3 (es) 2000-08-11 2014-07-18 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen un anticuerpo
US7157557B2 (en) 2001-02-23 2007-01-02 Immunex Corporation Increased recovery of active proteins
DE60322513D1 (de) 2002-02-27 2008-09-11 Immunex Corp Stabilisierte TNFR-Fc Formulierung mit Arginin
ATE464043T1 (de) * 2002-08-22 2010-04-15 Vasopharm Biotech Gmbh Pharmazeutische zusammensetzung enthaltend l- arginin
US20040115263A1 (en) 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
US8937045B2 (en) 2003-02-28 2015-01-20 Ares Trading S.A. Liquid formulations of tumor necrosis factor-binding proteins
US20060177444A1 (en) 2003-03-20 2006-08-10 Tatsuo Horizoe Concomitant drug as therapeutic agent for inflammatory bowel disease
AU2004262014B2 (en) 2003-08-01 2010-06-17 Amgen Inc. Crystalline tumor necrosis factor receptor 2 polypeptides
NZ546347A (en) 2003-10-14 2009-11-27 Intermune Inc Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
AU2005216847B2 (en) * 2004-02-27 2010-04-01 Cytiva Bioprocess R&D Ab A process for the purification of antibodies
JP5554466B2 (ja) 2004-03-01 2014-07-23 味の素株式会社 抗ヒトＴＮＦ−α抗体活性低下抑制剤
CN104593277A (zh) 2004-03-05 2015-05-06 帝斯曼知识产权资产管理有限公司 用于通过连续灌注和交互切向流来培养细胞的方法
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
EP1885388B1 (en) 2005-05-10 2013-09-11 Biogen Idec MA Inc. Treating and evaluating inflammatory disorders
CN101237890A (zh) 2005-06-10 2008-08-06 中外制药株式会社 含有葡甲胺的蛋白质制剂的稳定剂及其利用
WO2007076354A2 (en) 2005-12-20 2007-07-05 Bristol-Myers Squibb Company Stable protein formulations
US7390786B2 (en) 2005-12-21 2008-06-24 Wyeth Protein formulations with reduced viscosity and uses thereof
AU2007212147A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
SG170750A1 (en) 2006-03-17 2011-05-30 Biogen Idec Inc Stabilized polypeptide compositions
WO2007124082A2 (en) 2006-04-21 2007-11-01 Amgen, Inc. Buffering agents for biopharmaceutical formulations
US20080112953A1 (en) 2006-10-06 2008-05-15 Amgen Inc. Stable formulations
PE20080857A1 (es) 2006-10-20 2008-08-19 Amgen Inc Formulaciones a base de polipeptidos estables
ES2541546T3 (es) 2006-11-03 2015-07-21 Wyeth Llc Sustancias que inhiben la glucólisis en cultivo celular
CA2790018C (en) 2006-12-21 2015-02-03 Amgen Inc. Formulations
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
CN101679941A (zh) 2007-03-02 2010-03-24 惠氏公司 在细胞培养物中使用铜和谷氨酸盐生产多肽
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
LT2170390T (lt) 2007-06-14 2019-01-10 Biogen Ma Inc. Natalizumabo antikūnų kompozicijos
CA2707483A1 (en) 2007-11-30 2009-06-11 Wolfgang Fraunhofer Protein formulations and methods of making same
MX2010009398A (es) * 2008-02-29 2010-11-12 Biogen Idec Inc Proteinas de fusion de inmunoglobulinas purificadas y los metodos para su purificacion.
US9238810B2 (en) * 2008-06-05 2016-01-19 Affibody Ab Polypeptide
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
US8536316B2 (en) 2009-08-07 2013-09-17 Emd Millipore Corporation Methods for purifying a target protein from one or more impurities in a sample
KR20200111282A (ko) 2009-08-11 2020-09-28 제넨테크, 인크. 글루타민-비함유 세포 배양 배지에서의 단백질의 생성
US20120208986A1 (en) * 2009-10-20 2012-08-16 Wenger Marc D Use of mixed mode chromatography for the capture and purification of basic antibody products
EP2516467A2 (en) 2009-12-23 2012-10-31 Emergent Product Development Seattle, LLC Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
EP2563904B1 (en) 2010-04-26 2015-01-21 Novartis AG Improved cell culture medium
RU2600847C2 (ru) * 2010-05-10 2016-10-27 Интас Биофармасьютикалс Лимитед Жидкий состав полипептидов, содержащих fc-домен иммуноглобулина
WO2012013980A1 (en) 2010-07-30 2012-02-02 Arecor Limited Stabilized aqueous antibody compositions
EP2606119A1 (en) 2010-08-20 2013-06-26 Wyeth LLC Cell culture of growth factor-free adapted cells
EP2611904A2 (en) 2010-08-31 2013-07-10 Friesland Brands B.V. Culture medium for eukaryotic cells
US20120264920A1 (en) * 2010-10-11 2012-10-18 Abbott Laboratories Processes for purification of proteins
ES2759931T3 (es) 2011-04-20 2020-05-12 Sandoz Ag Formulaciones líquidas farmacéuticas estables de la proteína de fusión TNFR:Fc
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
DK2837680T3 (da) 2011-07-01 2020-04-27 Amgen Inc Mammaliacellekultur
CN103930124B (zh) 2011-07-01 2021-05-11 生物基因Ma公司 无精氨酸的tnfr：fc-融合多肽组合物及使用方法
EP2729482B1 (en) * 2011-07-08 2018-03-07 Merck Sharp & Dohme Corp. Method for purifying fc-fusion protein
JP6223338B2 (ja) * 2011-08-17 2017-11-01 アレス トレーディング ソシエテ アノニム 活性型ＴＮＦＲ−Ｆｃ融合タンパク質を製造する方法
US10493151B2 (en) * 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
PT2768525T (pt) 2011-10-18 2019-07-17 Coherus Biosciences Inc Formulações etanercept estabilizadas com iões de magnésio
IN2015KN00005A (sl) * 2012-07-09 2015-07-31 Coherus Biosciences Inc
ES2657377T3 (es) * 2012-09-11 2018-03-05 Coherus Biosciences, Inc. Etanercept plegado correctamente con alta pureza y excelente rendimiento
CA2916836C (en) * 2014-07-31 2017-12-12 Mtt Innovation Incorporated Numerical approaches for free-form lensing: area parameterization free-form lensing
US20160108634A1 (en) * 2014-10-16 2016-04-21 Ronald Uphold Pool Cover Hanger Device

Also Published As

Publication number Publication date
IN2015KN00452A (sl) 2015-07-17
JP6913066B2 (ja) 2021-08-04
MX2015003090A (es) 2015-07-14
MX2018012749A (es) 2020-11-12
DOP2015000055A (es) 2015-04-30
CO7400876A2 (es) 2015-09-30
PT2895188T (pt) 2018-02-08
AU2018247244B2 (en) 2020-05-28
IL267452A (en) 2019-08-29
HUE036524T2 (hu) 2018-07-30
CY1120062T1 (el) 2018-12-12
TWI716649B (zh) 2021-01-21
US10954295B2 (en) 2021-03-23
JP2015533797A (ja) 2015-11-26
SG11201501460RA (en) 2015-04-29
US20180037642A1 (en) 2018-02-08
AR092532A1 (es) 2015-04-22
US10947306B2 (en) 2021-03-16
US20190300602A1 (en) 2019-10-03
AU2013315750B9 (en) 2018-11-15
IL237311A0 (en) 2015-04-30
LT2895188T (lt) 2018-04-10
RS57013B1 (sr) 2018-05-31
MX360044B (es) 2018-10-19
JP2019038817A (ja) 2019-03-14
US11001627B2 (en) 2021-05-11
IL267452B (en) 2021-05-31
US20140072560A1 (en) 2014-03-13
US20190300601A1 (en) 2019-10-03
CN104902914B (zh) 2019-01-01
KR20200085937A (ko) 2020-07-15
KR20150056601A (ko) 2015-05-26
TWI609877B (zh) 2018-01-01
HRP20180182T1 (hr) 2018-04-20
PL2895188T3 (pl) 2018-06-29
CN104902914A (zh) 2015-09-09
PE20150996A1 (es) 2015-08-01
EA031324B1 (ru) 2018-12-28
WO2014043103A1 (en) 2014-03-20
ES2657377T3 (es) 2018-03-05
TW201803593A (zh) 2018-02-01
US20190330325A1 (en) 2019-10-31
SI2895188T1 (sl) 2018-05-31
AU2013315750A1 (en) 2015-03-05
JP2021100929A (ja) 2021-07-08
PE20200607A1 (es) 2020-03-10
KR102250937B1 (ko) 2021-05-12
NO2972131T3 (sl) 2018-04-21
US20190300600A1 (en) 2019-10-03
AU2018247244A1 (en) 2018-11-01
TW201425331A (zh) 2014-07-01
EP2895188A4 (en) 2016-05-25
US10954294B2 (en) 2021-03-23
EA201590542A1 (ru) 2015-07-30
CA2882551A1 (en) 2014-03-20
ECSP15014138A (es) 2016-01-29
EP2895188A1 (en) 2015-07-22
CN110051823A (zh) 2019-07-26
US10954293B2 (en) 2021-03-23
DK2895188T3 (en) 2018-02-26
IL237311B (en) 2019-07-31
AU2013315750B2 (en) 2018-07-12
CL2015000572A1 (es) 2016-02-05
KR102133699B1 (ko) 2020-07-14
EP2895188B1 (en) 2017-11-15

Similar Documents

Publication Publication Date Title
BR112015005161A2 (pt) etanercepte corretamente dobrado em alta pureza e excelente rendimento
BR112013019975A2 (pt) proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
HRP20201815T1 (hr) Nukleinske kiseline za liječenje alergija
GT200500254A (es) Proceso para la concentracion de anticuerpos y productos terapeùticos relacionados.
WO2014018858A3 (en) Multimeric fusion protein vaccine and immunotherapeutic
UY35195A (es) Composiciones y metodos para proteinas de accion prolongada
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
MX2013012231A (es) Composiciones nutricionales que tienen a-hica y a-cetoglutarato y metodos para utilizar las mismas.
BR112014008694A2 (pt) moléculas de ácido nucleico policistrônico recombinante
WO2013120012A3 (en) Cdim binding proteins and uses thereof
BR112014026531A2 (pt) proteínas de ligação de antígeno ligando cd30 humano
WO2013059559A3 (en) Compounds and methods for enhancing innate immune responses
BR112014015333A8 (pt) composições lipossomais de clorito ou clorato
BR112013020265A2 (pt) formas de rifaximina e uso das mesmas
MX2017001432A (es) Peptidos mimeticos de la apoe y mayor potencia para depurar el colesterol en plasma.
WO2016209978A3 (en) Thiol-ene based peptide stapling and uses thereof
BR112013029417A2 (pt) composições de vacina de matriz proteica incluindo policátions
BR112015000585A2 (pt) cepas mutantes de mycoplasma hyopneumoniae
BR112014002173A2 (pt) proteínas purificadas
BR112014000278A2 (pt) método para o preparo de um concentrado de imunoglobulinas polivalentes
WO2012149160A3 (en) Viruses modified with unnatural moieties and methods of use thereof
FI20115374A0 (fi) Uudet hypoallergeenit
EA201490012A1 (ru) Опсин-связывающие лиганды, композиции и способы их использования
IN2012DN00250A (sl)
BR112015013414A2 (pt) derivados de naftiridona e seu uso no tratamento, melhora ou prevenção de uma doença viral

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.